Drugs / CRS-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00327652 | Oct 2006 → Feb 2008 | carcinoma, liver and intrahepatic bile duct neoplasm, metastatic neoplasm | Anza Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRS-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00327652 ↗ |
| Known as | Live-attenuated Listeria monocytogenes | “Live-attenuated Listeria monocytogenes” NCT00327652 ↗ |
| Modality | Other / unclassified | “an investigational agent containing a live-attenuated strain of Listeria monocytogenes (Lm)” NCT00327652 ↗ |
| Route | Intravenous | “received a single intravenous dose of CRS-100” NCT00327652 ↗ |